118 related articles for article (PubMed ID: 19793348)
21. Cytogenetic and molecular genetic changes in malignant mesothelioma.
Musti M; Kettunen E; Dragonieri S; Lindholm P; Cavone D; Serio G; Knuutila S
Cancer Genet Cytogenet; 2006 Oct; 170(1):9-15. PubMed ID: 16965949
[TBL] [Abstract][Full Text] [Related]
22. A mouse model recapitulating molecular features of human mesothelioma.
Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068
[TBL] [Abstract][Full Text] [Related]
24. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.
Altomare DA; Menges CW; Pei J; Zhang L; Skele-Stump KL; Carbone M; Kane AB; Testa JR
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3420-5. PubMed ID: 19223589
[TBL] [Abstract][Full Text] [Related]
25. Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).
Chernova T; Murphy FA; Galavotti S; Sun XM; Powley IR; Grosso S; Schinwald A; Zacarias-Cabeza J; Dudek KM; Dinsdale D; Le Quesne J; Bennett J; Nakas A; Greaves P; Poland CA; Donaldson K; Bushell M; Willis AE; MacFarlane M
Curr Biol; 2017 Nov; 27(21):3302-3314.e6. PubMed ID: 29112861
[TBL] [Abstract][Full Text] [Related]
26. The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma.
de Assis LV; Locatelli J; Isoldi MC
Biochim Biophys Acta; 2014 Apr; 1845(2):232-47. PubMed ID: 24491449
[TBL] [Abstract][Full Text] [Related]
27. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.
Lecomte C; Andujar P; Renier A; Kheuang L; Abramowski V; Mellottee L; Fleury-Feith J; Zucman-Rossi J; Giovannini M; Jaurand MC
Cell Cycle; 2005 Dec; 4(12):1862-9. PubMed ID: 16319530
[TBL] [Abstract][Full Text] [Related]
28. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.
Suzuki Y; Murakami H; Kawaguchi K; Tanigushi T; Fujii M; Shinjo K; Kondo Y; Osada H; Shimokata K; Horio Y; Hasegawa Y; Hida T; Sekido Y
Mol Med Rep; 2009; 2(2):181-8. PubMed ID: 21475810
[TBL] [Abstract][Full Text] [Related]
29. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.
Cacciotti P; Barbone D; Porta C; Altomare DA; Testa JR; Mutti L; Gaudino G
Cancer Res; 2005 Jun; 65(12):5256-62. PubMed ID: 15958571
[TBL] [Abstract][Full Text] [Related]
30. Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells.
Wang H; Gillis A; Zhao C; Lee E; Wu J; Zhang F; Ye F; Zhang DY
Mutat Res; 2011 Aug; 723(2):171-6. PubMed ID: 21570478
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Carbone M; Yang H
Clin Cancer Res; 2012 Feb; 18(3):598-604. PubMed ID: 22065079
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines.
Kumar K; Rahman Q; Schipper H; Matschegewski C; Schiffmann D; Papp T
Oncol Rep; 2005 Sep; 14(3):743-50. PubMed ID: 16077986
[TBL] [Abstract][Full Text] [Related]
33. Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.
Andujar P; Lecomte C; Renier A; Fleury-Feith J; Kheuang L; Daubriac J; Janin A; Jaurand MC
Carcinogenesis; 2007 Jul; 28(7):1599-605. PubMed ID: 17272307
[TBL] [Abstract][Full Text] [Related]
34. NF2 alteration in mesothelioma.
Sekido Y; Sato T
Front Toxicol; 2023; 5():1161995. PubMed ID: 37180489
[TBL] [Abstract][Full Text] [Related]
35. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.
Sheffield BS; Tinker AV; Shen Y; Hwang H; Li-Chang HH; Pleasance E; Ch'ng C; Lum A; Lorette J; McConnell YJ; Sun S; Jones SJ; Gown AM; Huntsman DG; Schaeffer DF; Churg A; Yip S; Laskin J; Marra MA
PLoS One; 2015; 10(3):e0119689. PubMed ID: 25798586
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
[TBL] [Abstract][Full Text] [Related]
37. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.
Heintz NH; Janssen-Heininger YM; Mossman BT
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):133-9. PubMed ID: 20068227
[TBL] [Abstract][Full Text] [Related]
38. Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade.
Fujii M; Nakanishi H; Toyoda T; Tanaka I; Kondo Y; Osada H; Sekido Y
Cell Cycle; 2012 Sep; 11(18):3373-9. PubMed ID: 22918238
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.
Chernova T; Sun XM; Powley IR; Galavotti S; Grosso S; Murphy FA; Miles GJ; Cresswell L; Antonov AV; Bennett J; Nakas A; Dinsdale D; Cain K; Bushell M; Willis AE; MacFarlane M
Cell Death Differ; 2016 Jul; 23(7):1152-64. PubMed ID: 26891694
[TBL] [Abstract][Full Text] [Related]
40. Signal transduction in cancer.
Sever R; Brugge JS
Cold Spring Harb Perspect Med; 2015 Apr; 5(4):. PubMed ID: 25833940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
